AIDS, HIV & STDs Market Research Reports & Industry Analysis
HIV (human immunodeficiency virus) is a virus that attacks the immune system, making it difficult for the body to fight off infection and diseases. HIV infection eventually results in AIDS (acquired immunodeficiency syndrome). This conversion to AIDS may result after 12 or 13 years after the initial infection. Initial HIV symptoms are similar to those of the flu and include fatigue, fever, weight loss, and swollen lymph nodes in the neck, armpits, or groin. Although there is currently no cure for HIV infection, a combination of medications called Highly Active AntiRetroviral Therapy (HAART), and now referred to as AART, helps prolong life in many people. As noted above, person with HIV infection may live for many years before developing any signs of AIDS.
While HIV/AIDS isn’t found in the headlines as much as during the disease’s discovery, more people in the United States are living with HIV/AIDS than ever before. While the incidence of HIV infection in the United States was approximately 0.25% of the population ten to fifteen years ago, it is now approximately 0.47% -- and the population in general has grown.
For this reason, it is important to understand the trends in HIV/AIDS epidemiology and the potential impacts on economies and societies as a whole. These trends emphasize the strategic need for preventive approaches, clinical testing technologies and products, and new therapeutics. Many market research reports provide such information.
AIDS, HIV & STDs Industry Research & Market Reports
-
Syphilis Market - A Global and Regional Analysis: Focus on Treatment Type, Route of Administration, and Region - Analysis and Forecast, 2025-2035
... options. Syphilis, a highly infectious disease caused by the bacterium treponema pallidum, continues to be a major concern in public health, particularly in regions with high-risk populations such as those living with HIV, men who ... Read More
-
Global Gonorrhea Therapeutics Market 2025-2029
... provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current market scenario, the latest ... Read More
-
Global Markets for Infectious Disease Treatments
... A and B), hepatitis B, hepatitis C, respiratory syncytial virus (RSV) infection, tuberculosis (TB), herpes simplex virus (HSV) infection, malaria, rotavirus infection, and viral hemorrhagic fevers such as yellow fever, dengue, Lassa fever, Ebola fever, ... Read More
-
Human Immunodeficiency Virus (HIV) Rapid Test Kits
... expected to reach US$1.2 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. HIV Rapid Immunoassay Tests, one of the segments analyzed in the report, is expected to record a ... Read More
-
HIV-Associated Lipodystrophy
... CAGR of 2.2% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$119.2 Million by the end of the analysis ... Read More
-
Antiviral Drugs Market, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), By Type (Branded and Generics), By Application (HIV, Hepatitis, Herpes, Influenza, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... been witnessing steady growth over the past few years. Antiviral drugs, also known as antiviral agents or anti-infective medications, are a class of medication used specifically for treating infections caused by viruses. They work by ... Read More
-
The 2026-2031 World Outlook for HIV Therapeutics
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for HIV-AIDS Testing
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for HIV-1 Therapeutics
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for HIV-AIDS Immunoassay Diagnostics
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for HIV-AIDS Monitoring Tests
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Herpes Simplex Virus Infections
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for HIV and AIDS Testing
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for HIV-AIDS Drugs
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for HPV Vaccines
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Anal Fistula Treatments
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Herpes Simplex Virus Treatments
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for HIV and AIDS Therapeutics
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for HIV-AIDS Confirmatory Tests
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Blood Test in HIV Self-Testing
... country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using ... Read More
-
The 2026-2031 World Outlook for Genital Herpes Treatments
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for HPV and CMV Therapeutics
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for Gonorrhea Therapeutics
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for HIV Drugs
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Herpes Marker Testing
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
Research Assistance
